HLN
Get informed when a big investor buys or sells
+ FollowFebruary 25, 2026 - AI Summary
Undervalued by 139.2% based on the discounted cash flow analysis.
| Market cap | $40.79 Billion |
|---|---|
| Enterprise Value | $48.06 Billion |
| Dividend Yield | $0.19 (2.04%) |
| Earnings per Share | $0.36 |
| Beta | 0.25 |
| Outstanding Shares | 4,449,922,000 |
| P/E Ratio | 30.42 |
|---|---|
| PEG | 30.42 |
| Price to Sales | 3.27 |
| Price to Book Ratio | 3.27 |
| Enterprise Value to Revenue | 3.5 |
| Enterprise Value to EBIT | 16.6 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.52 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2237▲ 7.03% |
|---|---|
| Total Calls | 51,400▼ 25.62% |
| Total Puts | 11,500▲ 8.49% |
Holdings and activity of institutional investors.
| Ownership % | 12.68%▲ 0.17% |
|---|---|
| Total Invested | $5.68B▼ 0.69% |
| Investors Holding | 622▲ 11.00% |
No data
This committee provides crucial analysis and 'revenue estimates' for all tax legislation, directly influencing the tax policies that impact Haleon's financial performance and corporate structure.
This powerful committee controls taxation and trade policy, directly impacting Haleon's corporate profitability through tax rates and its global supply chain costs through tariffs and trade agreements.
This committee directly regulates the FDA, which oversees the approval, labeling, and marketing of many of Haleon's over-the-counter (OTC) drugs, medical devices, and supplements. Labor laws also directly impact its operations.
This committee's oversight of antitrust laws and intellectual property (IP) is critical for Haleon. Antitrust decisions affect mergers and market dominance, while IP protection is vital for its brands and product formulations.